Name | N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]-4-[(2,2,3,3,5,5,6,6-octadeuterio-4-methylpiperazin-1-yl)methyl]benzamide |
---|---|
Synonyms |
STI 571
Imatinib-d8 [2H8]-Imatinib Benzamide,4-[(4-methyl-1-piperazinyl-2,2,3,3,5,5,6,6-d8)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl] 4-(4-methyl-[2,2,3,3,5,5,6,6-D8]piperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-benzamide |
Description | Imatinib D8 (STI571 D8) is a deuterium labeled Imatinib (STI571). Imatinib is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity[1][2]. |
---|---|
Related Catalog | |
References |
Melting Point | 96-100 °C |
---|---|
Molecular Formula | C29H23D8N7O |
Molecular Weight | 501.65200 |
Exact Mass | 501.30900 |
PSA | 86.28000 |
LogP | 4.61210 |
Hazard Codes | Xi |
---|